Patient's Query
Hello doctor,
My aunt, who is 62 years old, has recently been diagnosed with stage two ovarian cancer. This news has been devastating for our entire family. From what I understand, the cancer has spread into the pelvic region but has not metastasized further yet. I want to learn more about what this stage of ovarian cancer means in terms of recommended treatment approaches and her overall prognosis moving forward.
As someone without much medical knowledge, could you explain the following:
I understand every case is different, but I am trying to be as informed as possible about what my aunt may face in the coming months.
Kindly help.
Hello,
Welcome to icliniq.com.
I read your query and can understand your concern.
Epithelial cancers of ovarian, fallopian tube, and peritoneal origin exhibit similar clinical characteristics and behavior. As such, these are often combined and define epithelial ovarian cancer (the most common type of ovarian cancer in the surface layer covering the ovary) in clinical trials and clinical practice. This topic will consider all three tumor origins under the heading EOC.
EOC is the most common cause of death among women with gynecologic malignancies and the fifth leading cause of cancer death in women. Only approximately twenty-five percent of women will be diagnosed with early-stage ovarian cancer, either confined to the ovary (stage I) or confined to the pelvis (stage II).
For women with these features, five-year disease-free survival rates range from forty to eighty percent. This compares with a five-year survival rate of at least ninety percent among women with well-differentiated (grade 1) tumors confined to the ovary (stage IA or IB). It is controversial whether women with grade 2 ovarian cancer should be considered as having high-risk disease and offered adjuvant therapy.
For women with high-risk disease (defined as stage IC or II, high-grade, or clear cell cancers of any stage), we recommend adjuvant chemotherapy. We also suggest the use of adjuvant chemotherapy for women with grade 2 tumors but acknowledge that observation, in the absence of other risk factors, may be an acceptable alternative for this subgroup of patients.
Intravenous chemotherapy (treatment in which anticancer drugs are given through a needle or tube inserted into a vein). As described above, adjuvant therapy is offered to women with early-stage EOC with high-risk features, typically between twenty-one and thirty-five days from primary debulking surgery, given some evidence of worsened survival with delay beyond thirty-five days. For such women, adjuvant intravenous chemotherapy is the preferred modality.
While the optimal adjuvant chemotherapy regimen is unknown, most clinicians offer treatment with a platinum-based doublet, such as Paclitaxel (a chemotherapeutic agent) and Carboplatin (a drug used to treat cancer), largely because of its demonstrated efficacy in the adjuvant therapy of women with advanced-stage EOC.
I hope this information will help you.
Kindly revert in case of further queries.
Same symptoms don't mean you have the same problem. Consult a doctor now!
Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.